Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138493 | 0.85 | EGFR (0.53) | GALR3NR2F2EGFR | |
| SCHEMBL11101615 | 0.83 | GALR3 (0.57) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL11102880 | 0.82 | GALR3 (0.56) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL11105460 | 0.79 | GALR3 (0.54) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL2480481 | 0.79 | GALR3 (0.45) | GALR3LMNARAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL4263771 | 0.78 | ALDH1A1 (0.57) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL4263769 | 0.78 | ALDH1A1 (0.57) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL11110706 | 0.77 | GALR3 (0.51) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL11100649 | 0.77 | GALR3 (0.57) | GALR3NR2F2EGFRLMNATNF | |
| SCHEMBL11596041 | 0.76 | RAB9A (0.43) | GALR3LMNARAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | GALR3 4172/4885NR2F2 2743/4885EGFR 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.